Osteal Therapeutics is a clinical-stage biopharmaceutical company developing novel combination drug/device therapies to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a seven-day vancomycin and tobramycin irrigation drug/device designed to deliver antibiotics directly to the joint space to treat periprosthetic joint infection (PJI). In clinical studies, 100% of patients were treated and received a new permanent joint prosthesis in seven days with more than 90% remaining infection-free after one year. VT-X7 has been evaluated in two multicenter randomized controlled trials, APEX and APEX-2; APEX met its primary endpoint in 2023 and APEX-2 recently met its primary endpoint and will be completed in late 2024. The FDA has granted VT-X7 Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations, and the company expects to seek approval upon APEX-2 completion. Osteal leverages locally delivered, concentrated antimicrobials and repurposes approved drugs for new local-delivery routes to address biofilm-driven musculoskeletal infections. Osteal Therapeutics is a Dallas, TX-based clinical-stage biopharmaceutical company developing musculoskeletal therapeutics to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a locally delivered antimicrobial in Phase 2 development aimed at treating periprosthetic joint infections (PJI). The company leverages concentrated, locally delivered antimicrobials to combat bacterial biofilms while minimizing off-target tissue exposure and adverse effects. Osteal employs a low-risk development approach by repurposing approved drugs with known safety and efficacy profiles for new routes of local delivery. It recently closed a $23M Series C financing to fund its next steps. Proceeds will support an NDA submission to the FDA and accelerate preparation for VT-X7's commercial launch; the company is led by CEO and President David Thompson. Osteal Therapeutics is a clinical-stage biopharmaceutical company creating a new category of combination therapies to treat musculoskeletal infections by delivering concentrated, locally applied antimicrobials to target biofilms. Its lead candidate, VT-X7, is a drug/device combination (vancomycin HCl and tobramycin sulfate for irrigation) designed as a seven-day therapy to deliver antibiotics directly to the joint space and surrounding tissue to treat chronic periprosthetic joint infection (PJI). VT-X7 completed an open-label Phase 2 trial in which 100% of VT-X7 patients were treated and received a new permanent joint prosthesis in seven days and 93% remained infection-free at one year. The company is currently enrolling APEX, a randomized controlled study of VT-X7 versus the current standard of care (two-stage exchange arthroplasty). The FDA has granted VT-X7 Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations. Osteal plans to use new capital to advance VT-X7 into later-stage clinical trials and to fund additional research programs.

Total raised

$103M

Funding rounds

3

Latest round

Series D

Latest activity

Jun 2024